A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

  • STATUS
    Not Recruiting
  • End date
    May 24, 2024
  • participants needed
    2400
  • sponsor
    Eli Lilly and Company
Updated on 26 January 2021
Investigator
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Primary Contact
DIM Clinica Privada (3.1 mi away) Contact
+223 other location
cardiovascular disease
body mass index
hypertension
dyslipidemia
glucose intolerance
overweight and obesity

Summary

This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase. The main phase of the study will last 72 weeks (14 visits). Participants with prediabetes will continue in the extension for another 2 years.

Details
Condition Overweight, Obesity
Treatment Placebo, Tirzepatide
Clinical Study IdentifierNCT04184622
SponsorEli Lilly and Company
Last Modified on26 January 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note